Physitrack PLC — Transactions under Share Buy-back Programme
Physitrack PLC — Transactions under Share Buy-back Programme
Physitrack PLC (Nasdaq First North Growth Market Stockholm: PTRK) (“Physitrack” or the “Company”) announced on 21 July 2026 a share buy-back programme, which commenced on 10 August 2026. The Company reports below the transactions undertaken under the programme during the week of 24 August 2026 to 28 August 2026 (inclusive), in accordance with Article 5 of the Market Abuse Regulation (EU) 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052.
Summary of transactions
| Period | 24 August 2026 – 28 August 2026 |
| Total shares repurchased during the week | 6,673 |
| Volume-weighted average price paid (SEK) | 8.0964 |
| Total consideration paid (SEK) | 54,027.06 |
| Total shares held by the Company (treasury) following these transactions | 21,173 |
| Total outstanding shares in the Company | 16,260,766 |
| Treasury holding as % of issued share capital | 0.13% |
Individual transactions
| Date | Quantity | Average price (SEK) |
| 2026-08-24 | 1,000 | 8.08 |
| 2026-08-25 | 2,000 | 8.16 |
| 2026-08-26 | 1,500 | 8.16 |
| 2026-08-27 | 1,500 | 8.0133 |
| 2026-08-28 | 673 | 7.9749 |
The buy-back programme is conducted within the safe harbour provided by Article 5 of MAR and Commission Delegated Regulation (EU) 2016/1052. The purpose of the programme is to enable the Company to meet its obligations under its employee share plans. The programme is executed by Pareto Securities on a non-discretionary basis on Nasdaq First North Growth Market Stockholm.
Notification details
| 1. Issuer | Physitrack PLC, LEI 213800PC4QYNWHPCP774 |
| 2. Instrument/ISIN | Ordinary shares / GB00BYX22590 |
| 3. Trading venue | Nasdaq First North Growth Market Stockholm (PTRK) |
| 4. Currency | SEK |
| 5. Purpose of buy-back | To meet the Company's obligations under its employee share plans (a permitted purpose under Article 5(2) of MAR) |
| 6. Executing broker | Pareto Securities (non-discretionary mandate) |
This disclosure is made in accordance with Physitrack PLC's obligations under Article 5 of MAR and Commission Delegated Regulation (EU) 2016/1052.